Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Product Launch

18 Nov 2005 07:00

Original Investments PLC18 November 2005 Original Investments PLC ("Original Investments" or "the Company") Commercial product launch from Acrobot Visualisation software, enabling orthopaedic surgeons to producethree-dimensional bone surface models from Computed Tomography (CT) scans forpre-operative surgical planning, is launched today by The Acrobot Company("Acrobot"). Acrobot is a spin-out company from Imperial Innovations, the technologycommercialization company of Imperial College, London, and develops surgicalsystems for minimally-invasive, bone-conserving orthopaedic surgery. TheAIM-quoted company Original Investments (formerly BioProjects International)owns 25% of Acrobot's equity. The new software, called the Acrobot(R) Planner, is Acrobot's first commercialproduct and is being provided free of charge to surgeons who register to use it.Acrobot will receive fees for data preparation and bone modeling. The Acrobot(R) Planner gives the user the ability to visualise a patient's threedimensional bone surface models built from CT scans. The visualisation isinteractive and the user can select and position implant models onto the bones,evaluate the resulting range of motion, and produce reports. "The software will enable surgeons to assess accurately the exact requirementfor each operation and precisely plan the procedure beforehand," says Dr. PaulaGomes, Acrobot's Director of Operations. "It will help to reduce surgicalerrors, surgeon's stress, and overall procedure costs and times. Radiologistswill also use the software to produce enhanced reports." Further uses for the software will be as a powerful tool for teaching and alsogenerating visual material for presentations. Acrobot provides a commercial service for Acrobot(R) Planner users by taking theraw CT DICOM data, segmenting them and building bone surface models from theinformation. The user can import these patient-specific models into thesoftware, and perform hip resurfacing pre-operative surgical planning and/ orimpingement analysis. The data processing service removes the need for the userto be involved in time-consuming routine data preparation tasks. The Acrobot(R) Planner has been developed by the Acrobot team at the company'slaboratories in London's Leathermarket. It is the first of a number of relatedproducts to be produced by Acrobot, which was founded six years ago by ImperialInnovations as a collaboration to combine the skills of clinicians andacademics. Acrobot is initially focusing on developing precision surgical systems forminimally-invasive techniques in knee and hip replacement. With each product theoverall aims are to reduce error, increase accuracy and enable more difficultsculpted surfaces to be achieved for the new generation of 'resurfacing' orpartial joint implants. Products planned for launch in 2006 include the Acrobot(R) Navigation System,which provides visual guidance for the surgeon and is now undergoing regulatoryapproval, and the Acrobot Hands-On Robotic System, which has already beensuccessfully proven in clinic for unicompartmental knee arthroplasty. "We are delighted that our faith in Acrobot is beginning to bear commercialfruit," said Terry Bond, managing director of Original Investments. "Four yearsago we were the first investors outside Imperial College to provide seed-cornfunding for the company and we have continued to support it through the variousstages of its development." Further information on Original Investments PLC from Terry Bond, ManagingDirector, 01235 834734. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
14th Dec 20217:00 amRNSHalf-year Report
6th Dec 20217:00 amRNSNotice of Half-year results
18th Nov 20217:00 amRNSDPYD screening recommended in Spain
28th Oct 20217:00 amRNSRanger® Technology to be presented at Labroots
26th Oct 20217:00 amRNSHalf-year Trading update
29th Sep 20217:00 amRNSResult of AGM
28th Sep 20213:00 pmRNSAGM update
28th Sep 20217:00 amRNSAGM Statement
15th Sep 20217:00 amRNSShare option awards
1st Sep 20217:00 amRNSISO 15189:2012 accreditation received
1st Sep 20217:00 amRNSNotice of AGM and Annual Report 2021
19th Aug 202112:04 pmRNSCOVID-19 Surge testing contract
11th Aug 20217:01 amRNSEarn-out Milestone, Issue of Equity & TVR
11th Aug 20217:00 amRNSAudited Final results&unaudited Q1 business update
6th Aug 20217:00 amRNSConfirmation of Results Date
23rd Jul 20217:00 amRNSNotice of Results
1st Jul 202111:09 amRNSHolding(s) in Company
21st Jun 20217:00 amRNSSecond Strategic Partner for Coastal Genomics
18th Jun 20217:00 amRNSContract Award: DPYD testing kits for NHS Wales
17th Jun 20214:32 pmRNSExercise of Options
9th Jun 20217:00 amRNSMulti-year licence and supply agreement
21st May 20214:30 pmRNSDirector/PDMR Shareholding
19th May 20217:00 amRNSDistribution Partnership
18th May 20217:00 amRNSLaunch of IONA Care NIPT service offering
17th May 20217:00 amRNSFurther testing service agreement for MHC
29th Apr 20217:00 amRNSFull year Trading update
26th Apr 20217:00 amRNSFurther National Microbiology Framework awards
19th Apr 20211:21 pmRNSFurther National Microbiology Framework contract
19th Apr 20217:00 amRNSNational Framework contract award
12th Apr 20217:00 amRNSEarn-out Milestone, Issue of Equity & TVR
6th Apr 20212:43 pmRNSTesting service agreement with MyHealthCheckedplc
6th Apr 20211:54 pmRNSAgreement with Boots for COVID-19 sample kits
29th Mar 20214:00 pmRNSCOVID-19 update
23rd Mar 20217:00 amRNSShare option exercises and awards
19th Mar 20217:00 amRNSTwin Pregnancy study published using IONA® Test
17th Mar 20217:00 amRNSAppointment of VP of Sales North America
11th Mar 20217:00 amRNSYourgene Genomic Services portfolio expansion
1st Mar 20217:00 amRNSFirst US Supply Agreement
22nd Feb 20217:00 amRNSPartnership with NPH
10th Feb 202110:51 amRNSCorrection: Director / PDMR Shareholding
10th Feb 20217:00 amRNSDirector/PDMR Shareholding
8th Feb 20217:00 amRNSTrading update
13th Jan 20217:00 amRNSDPYD screening recommended in Belgium
11th Jan 20217:00 amRNSClarigene® SARS-CoV-2 Product Update
8th Jan 20217:00 amRNSIssue of Share Options
24th Dec 20207:00 amRNSCOVID-19 update
17th Dec 20207:00 amRNSHalf-year Report
15th Dec 20207:00 amRNSNotice of Half-year Results
2nd Dec 20207:00 amRNSDPYD kits recommended by NHS England
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.